J&J welcomes the MDR and IVDR revision proposal as a long awaited and targeted response to concerns raised by a broad range of stakeholders, including patients, healthcare providers, Notified Bodies and the MedTech industry. The proposed revision is an important contribution to Europes broader competitiveness and innovation agenda.
JJ
Johnson & Johnson
Company · Belgium · EU Transparency Register 75617941310-89
4
positions filed
in the 326 files tracked
4
legislative files
of 326 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 925 companies & groups on this site, they rank #206 by legislative files engaged — a count of participation, not a measure of influence.
6.2
declared lobbying FTE
self-declared
€900K+
declared costs / yr (floor)
9
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- EFPIA →
- MedTech Europe →
- AmCham EU
- Euromcontact →
- EJF
- CSR Europe
- EASSI
- EPC
- Digital Europe →
- Europen
- BusinessEurope →
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Companies & groups
- Head office
- New Brunswick, New Jersey, United states
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Johnson in PolicySpeak: request access →
Work at Johnson & Johnson? so we know who speaks for it.
Their record over time
Johnson & Johnson filed 4 positions between 10 Jun 2025 and 30 Jun 2026, across 4 of the 326 legislative files tracked here, attaching a full position paper 2 times.
2025 · 2 filed2026 · 2 filed
What they argued
The EU Biotech Act should outline how to ensure coherence and interplay across different (non)legislative frameworks impacting companies to avoid duplication or inconsistencies. The cumulative impact of overlapping or complex requirements in CT, health data and environmental management can hinder innovation.
Johnson & Johnson welcomes the European Commissions initiative to revise the EU Cybersecurity Act in response to the evolving threat landscape and the growing importance of cybersecurity for critical sectors, including healthcare and medical technologies.
As one of the largest scientific innovation companies in the world, Johnson & Johnson views quantum technologies as a transformative enabler for the future of health and scientific discovery. Quantum capabilities have the potential to redefine how we compute biology, accelerate drug discovery and diagnostics, scale secure data analysis, and unlock new solutions for patients, providers, and health systems globally.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- Wirtschaftskammer Österreich · 3 files in common
- Bitkom e.V. · 3 files in common
- Danish Chamber of Commerce · 3 files in common
- MedTech Europe · 3 files in common
Showing 5 of 77.
Is this your organization?
Everything on this page comes from Johnson & Johnson’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.